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Abstract 
Screening a 3-aminopyridin-2-one based fragment library against a 26-kinase panel 
representative of the human kinome identified 3-amino-5-(1-methyl-1H-pyrazol-4-yl)pyridin-
2(1H)-one (2) and 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one (3) as ligand efficient 
inhibitors of the mitotic kinase Monopolar Spindle 1 (MPS1) and the Aurora kinase family. 
These kinases are well recognised as attractive targets for therapeutic intervention for treating 
cancer. Elucidation of the binding mode of these fragments and their analogues has been 
carried out by X-ray crystallography. Structural studies have identified key interactions with 
a conserved lysine residue and have highlighted potential regions of MPS1 which could be 
targeted to improve activity and selectivity. 
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Introduction 
Protein kinases play key role in protein phosphorylation and cell signal transduction 
pathways representing an important therapeutic class.
1,2
 Deregulation of protein kinase 
activity, by over-expression or mutation, is intimately involved in cancer cell proliferation 
and survival.
1
 At least 28 small-molecule kinase inhibitors have been approved for use in the 
clinic, the majority of which target part of the highly conserved ATP-binding site, known as 
the hinge region.
1,3–8
 The highly conserved nature of this region presents a common challenge 
in developing kinase inhibitors, namely obtaining a desirable selectivity profile.
1,9,10
 High 
throughput screening against a kinase of interest in a target-centric manner is commonly used 
approach to identify small-molecule inhibitors. These inhibitors are subsequently screened 
against a panel of kinases in order to gain an understanding of their selectivity profile. 
Optimization can then lead to a more potent inhibitor that exhibits a desirable selectivity 
profile. Despite the successful applications of this method, various limitations have become 
clear. Several mechanisms by which cancer cells can escape inhibition of a single kinase have 
been reported.
11–14
 Additionally, protein kinase drug discovery efforts have focussed on a 
small number of well-validated targets.
15
 An alternative strategy is to target multiple nodes on 
a signalling network simultaneously giving the cancer cell a higher evolutionary barrier to 
overcome in order to achieve resistance.
16,17
 Although the highly conserved active site of 
protein kinases is often cited as a cause of poor selectivity of kinase inhibitors, it may be 
possible to exploit this poor selectivity to target multiple kinases.
12
 The recent increase in 
protein kinase panel screens can allow selectivity profiling of inhibitors to be carried out at a 
very early stage.
10,18–22
 Screening small-molecule libraries in a target-blind manner against a 
representative panel of kinases can identify novel chemotypes as inhibitors while giving 
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detailed information of their selectivity profiles. This approach may prove useful in 
identifying desirable selectivity profiles in order to discover small molecules that target 
multiple specific kinases that in combination are of clinical significance.  
INSERT FIGURE 1 
 
Figure 1: Properties of 3-aminopyridin-2-one fragment 1  
Owing to the successful application of structural biology to the development of small-
molecule protein kinase inhibitors from fragments, fragment-based drug design (FBDD) has 
become an area of sustained interest.
23,24
 Fragment-based hits are generally weak binders but 
form high quality interactions and can exhibit high ligand efficiency.
25,26
 Fragment compound 
libraries can sample a greater degree of chemical space than a lead like compound library 
containing a similar number of small molecules.
23,27–29
 Fragments often possess good 
physicochemical properties and can be subsequently grown or linked to other fragments in 
order to increase activity and selectivity.
25,26,30
 Despite their low molecular weight, fragments 
can possess a high degree of selectivity by exploiting very small structural differences.
18 
However, selectivity is not always maintained between a fragment and related lead-like 
molecules.
18
 The selectivity of small molecules tested against a panel of kinases can be 
quantitatively described by their selectivity score (S), the ratio of kinases in the panel that are 
inhibited above a certain % inhibition, e.g. Scompound(50%).
21
 The score ranges from 0 to 1, 
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with 1 representing a completely non-selective inhibitor. A similar scoring function can be 
used to describe the selectivity score of a kinase (Skinase(50%)). This represents the ratio of 
compounds in a screening library that inhibit the particular kinase greater than 50%.
10
 
The identification of novel kinase inhibitor scaffolds is highly desirable in order to develop 
selective kinase inhibitors. Small-molecule inhibitors of Interleukin-2-inducible T-cell kinase 
(Itk) that are based on the 3-aminopyridin-2-one fragment 1 have been reported.
31
 Despite 
derivatisation of 1 yielding potent Itk inhibitors,
31
 this 3-aminopyridin-2-one fragment is 
poorly represented in small-molecule protein kinase modulators. This fragment is capable of 
forming multiple hydrogen bonds to the backbone of the hinge region, possesses good 
physicochemical properties
30
 and contains several suitable points for derivatisation (Figure 
1), representing a good starting point for the synthesis of a kinase-targeted fragment library. 
Herein, we report the synthesis and kinase profiling of a 3-aminopyridin-2-one based 
fragment library against a panel of 26 protein kinases. This led to the rapid identification of 
aminopyridin-2-one derivatives as a novel class of inhibitors of monopolar spindle 1 (MPS1) 
and Aurora kinases, two kinases intimately involved in mitosis. 
Results and Discussion 
INSERT FIGURE 2 
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Figure 2: Synthesis and members of 3-aminopyridin-2-one based fragment library. i: 
Aryl/Heteroaryl boronic acid, Pd2(dba)3, XPhos, K3PO4, n-butanol, 120 °C. ii: TMS-Cl, NaI, 
acetonitrile. iii: Bis(pinacolato)diboron, KOAc, Pd(dppf)Cl2, dioxane 80 °C. iv: 
Aryl/Heteroaryl halide, Pd(PPh3)4, Na2CO3, toluene, EtOH, H2O, 100 °C. v: TMS-Cl, NaI, 
acetonitrile. vi: H2SO4, 120 °C. vii: NaOH, Br2. For synthesis of compound 4, see 
supplementary data Figure 1, and for the synthesis of compounds 7 and 8, see supplementary 
data Figure 2. 
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A fragment library based on 3-aminopyridin-2-one was synthesised from 5-bromo-2-
methoxypyridin-3-amine by first introducing a variety of aromatic and heteroaromatic groups 
at the 3-aminopyridin-2-one C5-position under standard Suzuki cross-coupling conditions, 
followed by deprotection of the 3-amino-2-methoxy-pyridine intermediates by generating 
TMS-I in situ (Figure 2).
32
 3-Amino-6-methyl-5-(pyridin-4-yl)pyridin-2-one (15) was 
synthesised in two steps from the phosphodiesterase inhibitor Milrinone (13). Hydrolysis of 
the nitrile 13 to the carboxamide intermediate 14 by treatment with concentrated sulfuric acid 
at 120 °C, was followed by a Hofmann rearrangement to give compound 15 (Figure 2).
33
 
In order to test the biochemical activity of our fragment library, a panel of 26 structurally 
diverse protein kinases was used. The panel represented members of the TK, CMGC, 
CAMK, CK1 and AGC families (Supplementary data Table 1). By choosing this panel, we 
recognised that the exact composition of a kinase panel could affect selectivity scores in 
particular for small assay panels, as suggested by Karaman et al.
21
 Compounds 1-3, 5-8 and 
15 were initially screened at a single concentration of 100 µM using a mobility shift-based 
biochemical assay from Caliper Life Sciences.
34
 The 3-aminopyridin-2-one fragment 1 
showed very little activity against our kinase panel with the exception of Aurora A and 
AKT2, 58% and 77% inhibition at 100 M, respectively (Figure 3, and Supplementary data 
Table 2). This may be expected from screening such a small fragment at a relatively low 
concentration, as even weak activity such as a Ki of 1 mM would give a ligand efficiency of 
0.52. Introduction of an aromatic ring at the C5-position generally resulted in an increase in 
biochemical activity.  Introduction of a N-methylpyrazole (compound 2) gave high 
percentage inhibition against a large number of kinases in the panel, resulting in a S(50%) of 
0.77 (Supplementary data Table 2) showing good potency but poor selectivity. The 
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phosphodiesterase inhibitor Amrinone (3), which contains a 4-pyridyl substitution, showed 
reasonable activity against four members of the panel (MPS1, CHK1, PKC and PKA), 
resulting in a S(50%) score of 0.08. Introduction of a methyl group at the C6-position of the 
aminopyridinone 3 gave compound 15 which showed low potency against the 26-kinase 
panel, only one kinase, Aurora B, was inhibited by greater than 50 % (77%) (Figure 3, and 
Supplementary data Table 2). 
INSERT FIGURE 3 
 
Figure 3: Line chart plotting the % inhibition at 100 µM A: 1 (Blue); 2 (Black); 3 (Green); 
15 (Grey); B: 5 (Blue); 6 (Black); 7 (Green); 8 (Grey). 
This may suggest the methyl group in compound 15 clashes with the protein-binding site, or 
induces an unfavourable conformation of the biaryl system. Retention of the exocyclic 3-NH2 
hydrogen bond donor in 3, accompanying by the removal of the hydrogen bond donor of the 
pyridone ring by conversion to the 3-amino-2-methoxy-pyridine analogue 5 resulted in a 
similar inhibitory  profile against MPS1 and Aurora B compared to compound 3 (Table 1). 
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An increase in activity against Aurora A, MPS1, ABL and CHK2 was observed when the 4-
pyridyl ring in compound 3 was substituted with a quinoline moiety, giving compound 6 
(Table 1, Figure 3). This analogue displayed a selectivity score S(50%) of 0.19 
(Supplementary data Table 2). A significant increase in activity across the entire panel was 
observed by the introduction of a substituted 2-aminopyrimidine moiety. 2-
Methylaminopyrimidine analogue 7 gave greater than 50% inhibition against 23 members of 
our 26-kinase panel (Figure 3) which resulted in a selectivity score S(50%) of 0.92 
(Supplementary data Table 2). Substitution of 2-methylaminopyrimidine in 7 with 2-
cyclopropylaminopyrimidine (compound 8) maintained activity against some members of the 
panel (AurA, MPS1, GSK3b, RSK1 PKD2) resulting in a selectivity score S(50%) of 0.35 
(Supplementary data Table 2). The poor selectivity of the aminopyrimidine analogues 7 and 8 
is possibly due to the aminopyrimidine acting as a hinge binding motif as previously 
reported.
18,35–38
  In order to validate these single point assay results, the dose-response curves 
for the compound libraries were obtained against Aurora A, Aurora B and MPS1 kinases. 
These kinases were selected because of their high Skinase(50%) against this compound library 
(Supplementary data Table 4) and their biological relevance in cancer cell proliferation and 
survival. The Aurora kinases are well recognised as attractive targets for cancer therapeutics 
and have extensively been investigated.
39,40
 The inhibition of MPS1 has been also proposed 
as an effective method for treatment of human cancers, with a relatively limited number of 
small-molecule MPS1 modulators being reported.
41–47
  
INSERT TABLE 1 
Table 1: Ki values and ligand efficiencies for 3-aminopyridin-2-one 
 library against Aurora A, Aurora B and MPS1 
Compd MPS1 Ki  µM AurA Ki  µM AurB Ki µM 
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(LE) (LE) (LE) 
1 > 1000 (-) 361.0 (0.59) 159.7 (0.64) 
2 94.7 (0.39) 7.5 (0.53) 3.2 (0.53) 
3 80.8 (0.40) 393.9 (0.30) 59.3 (0.41) 
4 236.4 (0.33) 99.5 (0.36) 102.7 (0.36) 
5 91.2 (0.37) 184.7 (0.31) 63.9 (0.38) 
6 30.2 (0.34) 76.3 (0.31) 41.7 (0.33) 
7 25.6 (0.39) 21.3 (0.40) 15.1 (0.41) 
8 11.0 (0.37) 30.2 (0.34) 12.0 (0.37) 
9 128.2 (0.38) 66.9 (0.41) 70.3 (0.40) 
10 269.3 (0.35) 89.6 (0.39) 18.7 (0.46) 
11 98.1 (0.39) 125.2 (0.38) 97.2 (0.39) 
12 367.3 (0.26) > 100 (-) 12.9 (0.37) 
13 > 100 (-) > 100 (-) > 100 (-) 
14 > 100 (-) > 100 (-) > 100 (-) 
15 > 100 (-) > 100 (-) 25.7 (0.42) 
Ki values were calculated from IC50 values using the  
Cheng-Prusoff equation.
48
 
IC50 values were obtained for an expanded version of the fragment library using the 
previously described mobility shift assay.
44
 Subsequently, Ki values were estimated from IC50 
values to allow better comparison of the activity against targets which were measured at 
different substrate concentrations (Supplementary data Table 1). The methylpyrazole 
analogue 2 showed good activity and high ligand efficiency against both Aurora A and B, 
with a more modest Ki value against MPS1 (Table 1). Compound 3 demonstrated modest 
inhibition and good ligand efficiency against MPS1 and Aurora B but lower inhibitory 
activity against Aurora A (Table 1). In agreement with data provided from the single point 
assay (Figure 3), compound 15 was only active against Aurora B displaying good ligand 
efficiency against this kinase (Table 1). The quinoline derivative 6 possessed reasonable 
activity against all three kinases but a reduction in LE was observed due to the increase in 
number of heavy atoms (Table 1). Introduction of 2-aminopyrimidine-based substituents 
(compounds 7, 8) resulted in an increase in potency compared to that observed for 3 (Table 
1), as it would be expected by the observed trends in percentage inhibition at 100 µM (Figure 
3). Both the methylaminopyrimidine derivative 7 and cyclopropylaminopyrimidine 8 were 
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potent in inhibiting all three kinases, maintaining high ligand efficiency (Table 1). 
Repositioning of the pyridine nitrogen by substituting the 4-pyridyl with a 3-pyridyl ring, 
compound 11, resulted in similar activity to that seen with 3, and removal of the nitrogen by 
replacement of the 4-pyridyl in 3 with a phenyl ring, compound 9, again gave comparable Ki 
values (Table 1). The pyrimidine analogue 10 showed a decrease in activity against MPS1 
compared to compound 3, and a moderate increase in inhibitory activity against Aurora A 
and B (Table 1). Compound 12 showed selectivity for inhibition of Aurora B over Aurora A 
and MPS1 (Table 1).  
INSERT FIGURE 4 
 
Figure 4: X-Ray crystal structure of 2 (carbon atoms in yellow) bound to MPS1 (3.00 Å) 
with Fo-Fc omit map of 2 contoured at 3σ, clipped to 2 Å around 2 and displayed as a green 
mesh (PDB Code: 4CV8). 
The binding mode of these biaryl fragments to MPS1 was elucidated using X-ray 
crystallography. The crystal structure of the N-methylpyrazole analogue 2 in complex with 
MPS1 was determined with a resolution of 3.00 Å (Figure 4), and possessed the typical 
kinase tertiary structure. The positioning of the α C-helix and the DFG motif, and the 
presence of the catalytic C- and R-spine, suggest that MPS1 is in an active conformation.
44,49
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However, the activation loop (M671 - V684) could not be modelled, indicating that this 
region is not ordered, and no salt bridge was observed between K553 and E571. Clear 
electron density for the ligand was observed, identifying key hydrogen bonds formed from 
the aminopyridinone NH to the carbonyl of E603 (2.8 Å) and from the NH of G605 to the 
carbonyl of the 3-aminopyridin-2-one (2.7 Å). 
INSERT FIGURE 5 
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Figure 5: Synthesis of benzamidopyridin-2-one library. For synthesis of compound 24, see 
supplementary data. 
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Protein kinases frequently feature a hydrophobic channel that extends from the hinge region 
to the solvent exposed surface.
50
 Positioning of hydrophobic groups along this channel is a 
common strategy used to increase activity of kinase inhibitors.
50
 As substitution along this 
vector grants access to the solvent, it is also exploited to introduce solubilising groups. The 
amino acid sequence along this channel is less conserved between kinases than the hinge 
region and can also be exploited to gain selectivity.
50
 The crystal structure of compound 2 
bound to MPS1 suggests that this channel is accessible through modification of the 3-amino 
position (Figure 4).  Owing to this observation and the attributes of the channel that extends 
from the hinge region, a compound library based on benzamido derivatives of compound 3 
was synthesised including a sulfonamido-based derivative, compound 21 (Figure 5). The 
amide bond formation reaction and SNAr substitution reactions shown in Figure 5 have been 
previously reported for the preparation of compounds of this class.
51 
Compound 3 was 
selected as it displayed a less promiscuous kinase profile compared with 2, and it was 
hypothesised to have a kinase binding mode similar to that of fragment 2. A selection of 
members from this library was again screened against a panel of 26 protein kinases. 
INSERT FIGURE 6 
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Figure 6: Line chart plotting the % inhibition for compounds 16 (Blue); 17 (Green); 22: 
(Black); 24 (Grey).  
Screening a selection of analogues from this library against the panel of 26 kinases (16, 22, 
and 24 were screened at 30 M due to poor solubility; 17 tested at 100 M) generally 
demonstrated an increase in activity compared to compound 3 (Figures 3, 6). The benzamide 
16 demonstrated greater than 50% inhibition against eight members of the panel including 
MPS1 and Aurora A (S(50%) = 0.31; Supplementary data Table 3), and the 3-
methoxybenzamide analogue 17 also exhibited a selectivity score S(50%) of 0.31 (Figure 6, 
Supplementary data Table 3). The N-methylpiperazine analogue 22 displayed higher 
inhibitory potencies compared to 16 while maintaining a selectivity score S(50%) of 0.38 
(Figure 6, Supplementary data Table 3). Analogue 24 showed high percentage inhibition 
against a large number of kinases in the panel (Figure 6) with a S(50%) of 0.77 
(Supplementary data Table 3). This trend is in agreement with the poor selectivity observed 
with the structurally related fragments 7 and 8 (Figures 2, 3). The decrease in selectivity seen 
with analogue 24 relative to that observed with 16, 17, and 22 may be attributable to the 
aminopyrimidine system making additional or stronger interactions with the protein or acting 
as an alternative hinge binding motif.  As compounds 16, 17, 22, and 24 often demonstrated 
>50% inhibition against Aurora A, Aurora B and MPS1, inhibitory activities against these 
three kinases were again determined for the expanded compound library (Table 2).  The 
benzamide analogue 16 displayed a 15-fold increase in inhibitory activity against MPS1 
relative to that seen with 3, and also showed significantly higher inhibitory activity against 
Aurora A compared to that observed for compound 3 (Tables 1, 2).   
INSERT TABLE 2 
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Table 2: Ki values for benzamidopyridin-2-one library against  
Aurora A, Aurora B and MPS1 
Compd MPS1 Ki  µM 
(LE) 
AurA Ki  µM 
(LE) 
AurB Ki µM 
(LE) 
16 5.4 (0.33) 3.3 (0.34) 41.0 (0.27) 
17 24.8 (0.26) >100 (-) >100 (-) 
18 30.1 (0.24) >100 (-) 32.9 (0.23) 
19 >100 (-) >100 (-) >100 (-) 
20 >100 (-) >100 (-) >100 (-) 
21 >100 (-) >100 (-) >100 (-) 
22 4.8 (0.25) 14.9 (0.23) 5.5 (0.25) 
23 2.9 (0.27) 2.6 (0.27) 7.4 (0.25) 
24 3.2 (0.29) 17.3 (0.25) 3.6 (0.28) 
Ki values were calculated from IC50 values using the  
Cheng-Prusoff equation.
48
 
Mono- or disubstitution at the meta-position of the benzamide 16 with methoxy groups 
(compounds 17 and 18) was not well tolerated and equivalent fluorine substitutions 
(compounds 19 and 20) led to significant loss of activity (Table 2). The selectivity of 
compound 17 inhibiting MPS1 over Aurora A and Aurora B could possibly be explained by 
differences in the main chain conformation along the hydrophobic channel leading to the 
solvent exposed surface. Introduction of solubilising groups such as N-methylpiperazine 
(compound 22) and piperidine (compound 23) retained good activity against all three kinases 
but resulted in a reduction in ligand efficiency due to the increase in the number of heavy 
atoms (Table 2). It should be noted that compounds 16 and 23 have been reported by Charrier 
et al as Itk inhibitors.
31
 
INSERT FIGURE 7 
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Figure 7: X-Ray crystal structure of 23 (carbon atoms in yellow) bound to MPS1 (2.50 Å) 
with Fo-Fc omit map contoured at 3σ, clipped to 2 Å around 23 and displayed as a green 
mesh (PDB Code: 4CVA). 
In order to gain further structural insights into the binding modes of active members of this 
library, we successfully co-crystallised compounds 22 and 23 with MPS1 (Figures 7 and 8) 
with both structures showing a hydrogen bonding pattern to the amino acid backbone of the 
hinge region identical to that seen with fragment 2 bound to MPS1 (Figure 4). A further weak 
hydrogen bond between the nitrogen of the pyridyl ring in 23 and K553 was observed (2.6 Å) 
as shown in Figure 7. The piperidine and N-methyl piperazine groups present in compounds 
23 and 22, respectively, pointed out towards the solvent exposed surface as hypothesised 
(Figures 7, 8). The pyridyl ring is also involved in hydrophobic packing between V539 and 
I663 as shown in Figure 7. Further study of the protein environment of the pyridyl ring 
system may provide greater understanding of selectivity trends observed across the initial 
fragment library.  
INSERT FIGURE 8 
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Figure 8: X-ray crystal structure of 22 bound to MPS1 (PDB Code: 4CV9) (purple with I663 
and M602 shown as sticks) overlaid with the X-ray crystal structure of Aurora A (green with 
A273 and L210 shown as sticks).
40
 
Regarding MPS1 and Aurora kinases, it should be noted that MPS1 possesses a gatekeeper 
residue which is different to that seen in Aurora A and –B kinases. Where MPS1 has a 
flexible methionine residue (M602), Aurora A and -B have a leucine residue (L210 in Aurora 
A) as shown in Figure 8. In addition, MPS1 possesses an isoleucine (I663) residue that is 
involved in hydrophobic packing, the corresponding residue in Aurora A and B is alanine 
(A273 in Aurora A) (Figure 8). As previously stated, introduction of a benzamide or 
substituted benzamide group resulted in a loss in selectivity, both between MPS1 and Aurora 
A/B, and against the panel of 26 kinases. The hydrophobic channel, into which these groups 
project, is a common feature observed in kinases. Although the amino acid sequence of the 
hydrophobic channel is not as highly conserved as that of the hinge region, features of this 
channel are relatively similar. Since the benzamide analogues 16, 17, 22 and 24 show greater 
percentage inhibition against a large number of the kinases in the panel, it could be assumed 
19 
 
 
 
that they form non-directional hydrophobic interactions in this region. These findings are in 
agreement with previous reports suggesting that elaboration of selective fragments does not 
always result in selective compounds.
18
 
Conclusion 
In summary, screening a small compound library based on the 3-aminopyridin-2-one motif in 
a target-blind manner against a 26-kinase panel, representative of the kinome, identified hits 
that possess good activity and excellent ligand efficiency against MPS1, Aurora A and 
Aurora B. The binding mode of fragment 2 and compounds 22 and 23 with MPS1 was 
elucidated using X-ray crystallography providing structural information that could prove 
valuable in improving potency and obtaining a desirable selectivity profile. This scaffold may 
prove an attractive starting point for the development of potent inhibitors of MPS1 by 
providing vectors suitable for probing the P-loop, as in NMS-P715, or positioning of a 
hydrophobic group in a manner that further orders the activation loop.
41, 44
 
Experimental Section 
Chemistry: All anhydrous solvents and reagents were obtained from commercial suppliers 
(Sigma Aldrich, Acros, Fluorochem, Alfa Aesar) and used without further purification. 
Reactions were performed in oven-dried, round-bottom flasks fitted with rubber septa under 
an atmosphere of argon unless otherwise stated. Analytical thin layer chromatography (TLC) 
was performed on pre-coated aluminium sheets of silica (60 F254, Merck) and visualised by 
short-wave UV light. Reactions using microwave irradiation were performed in a Biotage
®
 
Initiator Sixty. Flash column chromatography was performed on a FlashMaster personal unit 
using isolute Flash silica columns or a Biotage SP1 purification system using Biotage Flash 
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silica cartridges. Ion exchange chromatography was performed using acidic Isolute Flash 
SCX-II cartridges. Silicon carbonate columns used were Isolute Si-Carbonate from Biotage.  
Semi-Preparative HPLC Method A: 1000 L standard injections (with needle rinse) of the 
sample, at 20 mg/mL concentration in DMSO, were made onto a Phenomenex Gemini 
column (10 m, 250 x 21.2 mm, C18, Phenomenex, Torrance, USA). Chromatographic 
separation at room temperature was carried out using Gilson GX-281 liquid handler system 
combined with a Gilson 322 HPLC pump (Gilson, Middleton, USA) over a 15 minute 
gradient elution from 10:90 to 100:0 methanol:water (both modified with 0.1% formic acid) 
at a flow rate of 20 mL/min. UV-Vis spectra were acquired at 254 nm on a Gilson 156 UV-
Vis detector (Gilson, Middleton, USA). Collection was triggered by UV signal, and collected 
using a Gilson GX-281 liquid handler system (Gilson, Middleton, USA). Raw data was 
processed using Gilson Trilution Software. 
1
H NMR spectra were recorded at 500 MHz on a Bruker Avance-500 using an internal 
deuterium lock. Chemical shifts were measured in parts per million (ppm) relative to 
tetramethylsilane ( = 0) using the following internal references for residual protons in the 
solvent: CDCl3 (  7.26), CD3OD (  3.32) and (CD3)2SO (  2.50). Data is presented as 
follows: chemical shift, integration, multiplicity, coupling constant (J) in Hz. 
13
C NMR 
spectra were recorded at 126 MHz on a Bruker Avance-500 using an internal deuterium lock. 
Chemical shifts were measured in parts per million (ppm) relative to tetramethylsilane ( = 0) 
using the following internal references: CDCl3 ( 77.0), CD3OD ( 49.0) and (CD3)2SO ( 
39.5). Data is presented as follows: chemical shift, integration, multiplicity, coupling constant 
(J) in Hz. 
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LC-MS analysis was performed on a Waters LCT with a Waters Alliance 2795 separations 
module and Waters 2487 dual wavelength absorbance detector coupled to a 
Waters/Micromass LCT time of flight mass spectrometer with ESI source. Analytical 
separation was carried out at 30 °C either on a Merck Chromolith SpeedROD column (RP-
18e, 50 x 4.6 mm) using a flow rate of 2 mL/min in a 3.5 minute gradient elution with 
detection at 254 nm or on a Merck Purospher STAR column (RP-18e, 30 x 4 mm) using a 
flow rate of 1.5 mL/min in a 3.5 minute gradient elution with detection at 254 nm. The 
mobile phase was a mixture of methanol (solvent A) and water (solvent B) both containing 
formic acid at 0.1%. Gradient elution was as follows: 1:9 (A/B) to 9:1 (A/B) over 2.25 min, 
9:1 (A/B) for 0.75 min, and then reversion back to 1:9 (A/B) over 0.3 min, finally 1:9 (A/B) 
for 0.2 min. 
 HRMS analysis was performed on an Agilent 1200 series HPLC and diode array detector 
coupled to a 6520 Quadrupole-Time of flight mass spectrometer with dual multimode 
APCI/ESI source. Analytical separation (Method A) was carried out at 30 °C on a Merck 
Purospher STAR column (RP-18e, 30 x 4 mm) using a flow rate of 1.5 mL/min in a 4 minute 
gradient elution with detection at 254 nm. The mobile phase was a mixture of methanol 
(solvent A) and water (solvent B) both containing formic acid at 0.1%. Gradient elution was 
as follows: 1:9 (A/B) to 9:1 (A/B) over 2.5 min, 9:1 (A/B) for 1 min, and then reversion back 
to 1:9 (A/B) over 0.3 min, finally 1:9 (A/B) for 0.2 min. The following references masses 
were used for HRMS analysis: caffeine [M+H]
+
 195.087652; hexakis(1H,1H,3H-
tetrafluoropentoxy)phosphazene [M+H]
+
 922.009798, and hexakis(2,2-difluoroethoxy) 
phosphazene [M+H]
+
 622.02896 or reserpine [M+H]
+
 609.280657.  
3-Amino-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2(1H)-one (2) 
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5-Bromo-2-methoxypyridin-3-amine (100 mg, 0.493 mmol, 1 equivalent), 1-methyl-1H-
pyrazol-4-ylboronic acid (74.4 mg, 0.591 mmol, 1.2 equivalents), potassium phosphate (314 
mg, 1.478 mmol, 3 equivalents), 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (47 mg, 
0.099 mmol, 0.2 equivalents) and tris (dibenzylideneacetone)dipalladium(0) (22.55 mg, 0.025 
mmol, 0.05 equivalents) were dissolved in n-butanol (4 mL) and stirred at 110 °C for 3 hours. 
The solution was then cooled and filtered through a pad of Celite, which was then washed 
with methanol. The solution was concentrated and purified by SCX column (eluting at room 
temperature with 2 M ammonia in methanol) and concentrated. The residue was then 
dissolved in acetonitrile and sodium iodide (222 mg, 1.484 mmol, 3 equivalents) was added, 
followed by dropwise addition of trimethylsilyl chloride (0.190 mL, 1.484 mmol, 3 
equivalents) and the reaction mixture stirred for 16 hours. The solution was concentrated, 
taken up in methanol and purified by SCX column (eluting at room temperature with 2 M 
ammonia in methanol) to give a grey solid (25 mg, 27%). Rf = 0.36 (5% MeOH in EtOAc). 
mp: 264 °C. 
1
H NMR (500 MHz, DMSO-d6) 3.81 (3H, s), 5.09 (2H, s), 6.63 (1H, d, J = 2.3 
Hz), 6.83 (1H, d, J = 2.3 Hz), 7.59 (1H, s), 7.83 (1H, s), 11.38 (1H, s).
13
C NMR (126 MHz, 
DMSO-d6) 157.3 (C), 139.2 (C), 135.6 (CH), 127.0 (CH), 119.7 (C), 115.8 (CH), 112.3 (C), 
110.1 (CH), 39.0 (CH3). HRMS: Found 191.0932, calculated for C9H11N4O (M+H)
+
: 
191.0927. 
6-Methoxy-3,4’-bipyridin-5-amine (5) 
General Procedure A: 2-Dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (141 mg, 0.296 
mmol, 0.2 equivalents), tris(dibenzylideneacetone)dipalladium(0) (68 mg, 0.074 mmol, 0.05 
equivalents), 4-pyridinylboronic acid (218 mg, 1.773 mmol, 1.2 equivalents) and potassium 
phosphate (941 mg, 4.43 mmol, 3 equivalents), were added to 5-bromo-2-methoxypyridin-3-
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amine (300 mg, 1.478 mmol, 1 equivalent) in n-butanol (10 mL) and heated to reflux for 3 
hours. The reaction mixture was then cooled, filtered through a pad of Celite, which was 
subsequently washed with methanol and concentrated. The residue was then purified using a 
SCX column, eluting at room temperature with 2 M ammonia in methanol and concentrated 
to give a brown oil that crystallized upon standing to give a red solid (292 mg, 98%). Rf = 
0.45 (10% MeOH in CHCl3). mp: 204 °C. 
1
H NMR (500 MHz, DMSO-d6) 3.92 (3H, s), 5.17 
(2H, s), 7.24 (1H, d, J = 2.3 Hz), 7.58 (2H, dd, J = 1.7 Hz, 4.5 Hz), 7.82 (1H, d, J = 2.3 Hz), 
8.58 (2H, dd, J = 1.6 Hz, 4.5 Hz).
13
C NMR (126 MHz, DMSO-d6) 153.1 (C), 150.6 (CH), 
145.6 (C), 133.3 (C), 131.2 (CH), 127.5 (C), 121.1 (CH), 116.6 (CH), 53.6 (CH3). HRMS: 
Found 202.0986, calculated for C11H12N3O (M+H)
+
: 202.0975. 
2-Methoxy-5-phenylpyridin-3-amine 
Prepared using general procedure A to give a brown solid (174 mg, 88%): 2-
dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (94 mg, 0.197 mmol, 0.2 equivalents), 
tris(dibenzylideneacetone)dipalladium(0) (45 mg, 0.049 mmol, 0.05 equiv-alents), 4-
phenylboronic acid (144 mg, 1.182 mmol, 1.2 equivalents), potassium phosphate (627 mg, 
2.96 mmol, 3 equivalents), 5-bromo-2-methoxypyridin-3-amine (200 mg, 0.985 mmol, 1 
equivalent) and n-butanol (7 mL). Rf = 0.35 (DCM:EtOAc 1:1). mp: 218 °C. 
1
H NMR (500 
MHz, CDCl3) 3.87 (2H, s), 4.05 (3H, s), 7.13 (1H, d, J = 2.1 Hz), 7.32 - 7.37 (1H, m), 7.42 - 
7.46 (2H, m), 7.51 - 7.54 (2H, m), 7.82 (1H, d, J = 2.1 Hz).
13
C NMR (126 MHz, CDCl3) 
152.6 (C), 138.5 (C), 133.3 (CH), 131.0 (C), 130.7 (C), 128.8 (CH), 127.1 (CH), 126.8 (CH), 
119.2 (CH), 53.5 (CH3). HRMS: Found 201.1030, calculated for C12H13N2O (M+H)
+
: 
201.1022. 
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3-Amino-5-phenyl-pyridin-2-one (9) 
General Procedure B: Trimethylsilyl chloride (0.55 mL, 4.34 mmol, 5 equivalents) was 
added dropwise to a solution of 2-methoxy-5-phenylpyridin-3-amine (174 mg, 0.869 mmol, 1 
equivalent) and sodium iodide (651 mg, 4.34 mmol, 5 equivalents) in acetonitrile (6 mL) and 
stirred for 2 hours at room temperature. The solvent was then removed under reduced 
pressure and the residue purified using a SCX column to give a grey solid (32 mg, 20%). Rf = 
0.51 (5% MeOH in CHCl3). mp: 291 °C. 
1
H NMR (500 MHz, DMSO-d6) 5.16 (2H, s), 6.81 
(1H, d, J = 2.4 Hz), 6.93 (1H, d, J = 2.4 Hz), 7.25 (1H, tt, J = 1.2 Hz, 7.3 Hz), 7.36 - 7.40 
(2H, m), 7.44 - 7.48 (2H, m), 11.53 (1H, br s).
13
C NMR (126 MHz, DMSO-d6) 157.5 (C), 
139.2 (C), 138.0 (C), 129.3 (CH), 126.9 (CH), 125.7 (CH), 119.6 (C), 117.8 (CH), 110.2 
(CH). HRMS: Found 187.0877, calculated for C11H11N2O (M+H)
+
: 187.0866. 
2-Methoxy-5-(pyrimidin-5-yl)pyridin-3-amine 
Prepared using general procedure A to give a brown solid (142 mg, 72%): 2-
dicyclohexylphosphino-2,4,6-triisopropylbiphenyl (94 mg, 0.197 mmol, 0.2 equivalents), 
tris(dibenzylideneacetone)dipalladium(0) (45 mg, 0.049 mmol, 0.05 equivalents), 
pyrimidinyl-5-boronic acid (124 mg, 1.182 mmol, 1.2 equivalents), potassium phosphate 
(627 mg, 2.96 mmol, 3 equivalents), 5-bromo-2-methoxypyridin-3-amine (200 mg, 0.985 
mmol, 1 equivalent) and n-butanol (7 mL). Rf = 0.3 (DCM: EtOAc 1:1). mp: 233 °C. 
1
H 
NMR (500 MHz, DMSO-d6) 3.92 (3H, s), 5.19 (2H, s), 7.21 (1H, d, J = 2.2 Hz), 7.78 (1H, d, 
J = 2.2 Hz), 9.02 (2H, s), 9.16 (1H, s).
13
C NMR (126 MHz, DMSO-d6) 157.4 (CH), 154.6 
(CH), 152.9 (C), 133.4 (C), 132.0 (C), 131.0 (CH), 124.2 (C), 116.7 (CH), 53.6 (CH3). 
HRMS: Found 203.0929, calculated for C10H11N4O (M+H)
+
: 203.0927. 
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3-Amino-5-(pyrimidin-5-yl)pyridin-2(1H)-one (10) 
Prepared using general procedure B to give a brown solid (77 mg, 68%):  2-methoxy-5-
(pyrimidin-5-yl)pyridin-3-amine (122 mg, 0.603 mmol, 1 equivalent), trimethylsilyl chloride 
(0.386 mL, 3.02 mmol, 5 equivalents) and sodium iodide (452 mg, 3.02 mmol, 5 equivalents) 
in acetonitrile (5 mL). Rf = 0.57 (DCM:EtOAc 1:1). mp: 240 °C. 
1
H NMR (500 MHz, 
DMSO-d6) 5.26 (2H, s), 6.82 (1H, d, J = 2.4 Hz), 7.20 (1H, d, J = 2.4 Hz), 8.94 (2H, s), 9.06 
(1H, s).
13
C NMR (126 MHz, DMSO-d6) 157.9 (C), 156.7 (CH), 153.7 (CH), 139.6 (C), 131.6 
(C), 119.5 (CH), 113.2 (C), 108.6 (CH). HRMS: Found 189.0711, calculated for C9H9N4O 
(M+H)
+
: 189.0771. 
N-(2-Oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl)benzamide (16) 
General procedure C: Benzoyl chloride (0.062 mL, 0.53 mmol, 1 equivalent) was added 
dropwise to 3-amino-5-(pyridin-4-yl)pyridin-2-one (100 mg, 0.53 mmol, 1 equivalent) in 
pyridine (3 mL) and the mixture was stirred for 16 hours at room temperature. The solvent 
was removed under reduced pressure and the residue taken up in methanol and filtered to 
give the desired product as a light-yellow solid (41 mg, 27%). Rf = 0.58 (1:1 DCM:EtOAc). 
mp: 291˚C. 1H NMR (500 MHz, DMSO-d6) 7.54 - 7.67 (5H, m), 7.82 (1H, d, J = 2.5 Hz), 
7.90 - 8.00 (2H, m), 8.52 - 8.65 (2H, m), 8.77 (1H, d, J = 2.5 Hz), 9.39 (1H, s), 12.60 (1H, 
s).
13
C (126 MHz, DMSO-d6) 165.6 (C), 157.8 (C), 150.7 (CH), 144.0 (C), 134.2 (C), 132.7 
(CH), 129.5 (C), 129.3 (CH), 128.0 (CH), 127.7 (CH), 122.5 (CH), 120.2 (CH), 115.7 (C). 
HRMS: Found: 292.1075, calculated for C17H14N3O2 (M+H)
+
: 292.1086.  
 
3-Methoxy-N-(2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl)benzamide  (17) 
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Prepared using general procedure C to give a yellow solid (23 mg, 27%): 3-
methoxybenzoylchloride (0.038 mL, 0.27 mmol, 1 equivalent), 3-amino-5-(pyridin-4-
yl)pyridin-2-one (50 mg, 0.27 mmol, 1 equivalent). Rf = 0.69 (DCM:EtOAc 1:1). mp: 287 
°C. 
1
H NMR (500 MHz, DMSO-d6) 3.85 (3H, s), 7.21 (1H, dd, J = 1.7 Hz, 8.0 Hz), 7.43 - 
7.60 (3H, m), 8.17 - 8.31 (3H, m), 8.79 - 8.88 (3H, m), 9.46 (1H, s), 13.01 (1H, s).
13
C NMR 
(126 MHz, DMSO-d6) 165.6 (C), 159.9 (C), 158.1 (C), 152.3 (C), 142.8 (CH), 135.6 (C), 
132.3 (CH), 130.5 (CH), 129.6 (C), 122.6 (CH), 122.0 (CH), 119.8 (CH), 118.5 (CH), 113.1 
(CH), 55.9 (CH3). HRMS: Found 322.1182, calculated for C18H16N3O3 (M+H)
+
: 322.1186. 
3,5-Dimethoxy-N-(2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl)benzamide (18) 
Prepared using general procedure C to give a grey solid (32 mg, 34%): 3,5-
dimethoxybenzoylchloride (53.6 mg, 0.27 mmol, 1 equivalent), 3-amino-5-(pyridin-4-
yl)pyridin-2-one (50 mg, 0.27 mmol, 1 equivalent). Rf = 0.67 (DCM:EtOAc 1:1). mp: 280 
°C. 
1
H NMR (500 MHz, DMSO-d6) 3.83 (6H, s), 6.75 (1H, t, J = 2.2 Hz), 7.06 (2H, d, J = 2.2 
Hz), 7.61 (2H, dd, J = 4.6 Hz, 1.5 Hz), 7.83 (1H, d, J = 2.5 Hz), 8.59 (2H, dd, J = 4.6 Hz, 1.5 
Hz), 8.70 (1H, d, J = 2.5 Hz), 9.36 (1H, s), 12.58 (1H, s).
13
C NMR (126 MHz, DMSO-d6) 
165.4 (C), 161.1 (C), 157.9 (C), 150.7 (CH), 144.0 (C), 136.5 (C), 129.6 (C), 128.4 (CH), 
123.3 (CH), 120.1 (CH), 115.5 (C), 105.6 (CH), 104.3 (CH), 56.0 (CH3). HRMS: Found 
352.1291, calculated for C19H18N3O4 (M+H)
+
: 352.1292. 
3-Fluoro-N-(2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridin-3-yl)benzamide (19) 
Prepared using general procedure C to give a yellow solid (24 mg, 29%): 3-
fluorobenzoylchloride (0.028 mL, 0.27 mmol, 1 equivalent), 3-amino-5-(pyridin-4-
yl)pyridin-2-one (50 mg, 0.27 mmol, 1 equivalent). Rf = 0.51 (DCM:EtOAc 1:1). mp: 292 
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°C. 
1
H NMR (500 MHz, DMSO-d6) 7.50 (1H, td, J = 2.1 Hz, 8.2 Hz), 7.62 (1H, t, J = 8.0 
Hz), 7.77 (1H, d, J = 2.0 Hz), 7.82 (1H, d, J = 7.8 Hz), 8.23 (2H, d, J = 6.8 Hz), 8.26 (1H, 
brs), 8.82 (1H, d, J = 2.6 Hz), 8.83 (2H, d, J = 6.8 Hz), 9.62 (1H, s), 13.01 (1H, s). 
13
C (126 
MHz, DMSO-d6) 164.8 (C), 162.5 (d, J = 244.8 Hz, CF), 158.1 (C), 152.2 (CH), 142.8 (C), 
136.5 (d, J = 6.9 Hz, C), 132.7 (CH), 131.5 (d, J = 8.0 Hz, CH), 129.5 (C), 124.0 (d, J = 1.9 
Hz, CH), 123.5 (CH), 121.9 (CH), 119.6 (d, J = 21.2 Hz, CH), 114.9 (d, J = 23.0 Hz, CH), 
113.0 (C). HRMS: Found 310.0984, calculated for C17H13N3O2F (M+H)
+
: 310.0986. 
Kinase profiling: IC50 values for MPS1, Aurora A and Aurora B inhibition were determined 
as previously described,
44
 and Ki values were estimated from the mean IC50 values using the 
Cheng-Prusoff equation.
48
 The protocol for screening against the 26-kinase panel using a 
mobility shift assay is provided in the supplementary material. 
Crystallography: Co-crystals of 22 and 23 with MPS1 were produced by vapour diffusion 
using the hanging-drop method. The well buffer contained 0.2 M NaCO2H, 0.1 M BTP (pH 
7.5) and 15% (w/v) PEG 3350. The protein solution contained 11.59 mg/mL MPS1, 50 mM 
HEPES (pH 7.5), 150 mM NaCl and 5 mM DTT, supplemented with 1 mM compound (1% 
DMSO). Drops contained a 1:1 mixture of well buffer and protein solution. Crystals grew 
over 3 days at 18 °C. Harvested crystals were briefly transferred to cryoprotectant (22.5 % 
ethylene glycol, 15.5 % (w/v) PEG 3350 and 0.08 M Bis-Tris propane pH 7.5) and flash 
cooled in liquid nitrogen. Crystals of MPS1 in complex with 2 were obtained by back-
soaking a crystal of MPS1 with 23 in a new solution of 0.19 M NaCO2H, 0.095 M BTP (pH 
7.5), 14.25% PEG 3350 supplemented with 2 mM 2 for 48 hours prior to harvesting. 
Structure solution and refinement data are presented in supplementary material. 
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LEGENDS FOR FIGURES 
Figure 1: Properties of 3-aminopyridin-2-one fragment 1 
Figure 2: Synthesis and members of 3-aminopyridin-2-one based fragment library. i: 
Aryl/Heteroaryl boronic acid, Pd2(dba)3, XPhos, K3PO4, n-butanol, 120 °C. ii: TMS-Cl, NaI, 
acetonitrile. iii: Bis(pinacolato)diboron, KOAc, Pd(dppf)Cl2, dioxane 80 °C. iv: 
Aryl/Heteroaryl halide, Pd(PPh3)4, Na2CO3, toluene, EtOH, H2O, 100 °C. v: TMS-Cl, NaI, 
acetonitrile. vi: H2SO4, 120 °C. vii: NaOH, Br2. For synthesis of compound 4, see 
supplementary data Figure 1, and for the synthesis of compounds 7 and 8, see supplementary 
data Figure 2. 
Figure 3: Line chart plotting the % inhibition at 100 µM A: 1 (Blue); 2 (Black); 3 (Green); 
15 (Grey); B: 5 (Blue); 6 (Black); 7 (Green); 8 (Grey). 
Figure 4: X-Ray crystal structure of 2 (carbon atoms in yellow) bound to MPS1 (3.00 Å) 
with Fo-Fc omit map of 2 contoured at 3σ, clipped to 2 Å around 2 and displayed as a green 
mesh (PDB Code: 4CV8). 
Figure 5: Synthesis of benzamidopyridin-2-one library. For synthesis of compound 24, see 
supplementary data. 
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Figure 6: Line chart plotting the % inhibition for compounds 16 (Blue); 17 (Green); 22: 
(Black); 24 (Grey). 
Figure 7: X-Ray crystal structure of 23 (carbon atoms in yellow) bound to MPS1 (2.50 Å) 
with Fo-Fc omit map contoured at 3σ, clipped to 2 Å around 23 and displayed as a green 
mesh (PDB Code: 4CVA). 
Figure 8: X-ray crystal structure of 22 bound to MPS1 (PDB Code: 4CV9) (purple with I663 
and M602 shown as sticks) overlaid with the X-ray crystal structure of Aurora A (green with 
A273 and L210 shown as sticks).
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